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Abstract
Background: The overexpression of tumor necrosis factor (TNF)-α leads to systemic as well as local loss of bone and
cartilage and is also an important regulator during fracture healing. In this study, we investigate how TNF-α inhibition
using a targeted monoclonal antibody affects fracture healing in a TNF-α driven animal model of human rheumatoid
arthritis (RA) and elucidate the question whether enduring the anti TNF-α therapy after trauma is beneficial or not.
Methods: A standardized femur fracture was applied to wild type and human TNF-α transgenic mice (hTNFtg mice),
which develop an RA-like chronic polyarthritis. hTNFtg animals were treated with anti-TNF antibody (Infliximab) during
the fracture repair. Untreated animals served as controls. Fracture healing was evaluated after 14 and 28 days of
treatment by clinical assessment, biomechanical testing and histomorphometry.
Results: High levels of TNF-α influence fracture healing negatively, lead to reduced cartilage and more soft tissue
in the callus as well as decreased biomechanical bone stability. Blocking TNF-α in hTNFtg mice lead to similar
biomechanical and histomorphometrical properties as in wild type.
Conclusions: High levels of TNF-α during chronic inflammation have a negative impact on fracture healing. Our
data suggest that TNF-α inhibition by an anti-TNF antibody does not interfere with fracture healing.
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Background
Inflammatory diseases such as rheumatoid arthritis (RA),
do not only increase the risk of fractures [1,2] but may
also impair fracture healing by delaying the process and
leading to non-unions [3]. Tumor necrosis factor alpha
(TNF-α) is one of the main trigger of chronic inflamma-
tion in rheumatoid arthritis [4]. TNF-α is also critical
for the cause of systemic as well as local loss of bone
and cartilage during the course of disease [5]. The use
of TNF-α blocking antibodies ameliorates the symptoms
of this disease [6]. For instance, treatment with Infliximab,
a (chimeric) monoclonal TNF-α antibody, has reduced the
symptoms of RA patients [7]. Moreover, TNF-blocking
agents combine a strong anti-inflammatory potential lead-
ing to direct protection of bone and cartilage [8].
TNF-α is also an important regulator of fracture healing
[9]. Aside from Interleukin (IL)-1, −6 and −11, TNF-α is
active within the initial inflammatory phase of fracture
healing in macrophages and other inflammatory cells,
where it leads to neo-angiogenesis and induces osteogenic
differentiation of mesenchymal stem cells. In the terminal
remodeling phase of fracture healing, high expression of
TNF-α and IL-1 activates osteoclasts which degrade the
trabecular bone and osteoblasts which regenerate the
lamellar bone [10]. Previous studies have demonstrated
that lack of TNF-α signaling during fracture healing
impairs callus remodeling [11]. Thus, the TNF-α receptor
knockout mice show a delay in fracture healing caused by
a retarded development of cartilage, followed by chondro-
cyte apoptosis and remodeling of mineralized cartilage in
the late phase of fracture healing [12].
Therefore, TNF-α is an important mediator during dif-
ferent phases of fracture healing. However, the influence
of TNF-α blockade, as in treatment of RA patients under
chronic inflammatory conditions, is still unknown. A
retrospective study of rheumatoid patients treated with
TNF- α antagonists showed no decreased risk of fractures
* Correspondence: Melanie.Timmen@ukmuenster.de
2Institute for Experimental Muskuloskeletal Medicine IEMM, University
Hospital Muenster, Muenster, Germany
Full list of author information is available at the end of the article
© 2014 Timmen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Timmen et al. BMC Musculoskeletal Disorders 2014, 15:184
http://www.biomedcentral.com/1471-2474/15/184
[13]. Since TNF-α antibody therapy is widely used for
treatment of RA and chronic inflammation, the question
remains, whether the therapy should be continued in the
case of a fracture or should be suspended. Therefore,
we investigated the influence of TNF-α inhibition on
fracture healing in an established model of chronic
murine rheumatoid/inflammatory arthritis.
Methods
Mice and fracture model
Generation of heterozygous human tumor necrosis factor
transgenic (hTNFtg) mice (strain Tg197) were described
previously [14]. Homozygous hTNFtg mice develop a
chronic inflammatory arthritis due to the overexpres-
sion of human TNF which is acting on the murine TNF
receptor I. Disease starts at the age of 6 weeks and is
accompanied by local and systemic bone loss reflecting
inflammatory bone disease of human rheumatoid arth-
ritis. We used 12 week old, female mice for the fracture
experiments. Three groups of 20 mice, including wild type,
hTNFtg untreated and hTNFtg treated with a (chimeric)
antiTNF-α antibody (Infliximab, 10 mg/kg, 3 times weekly,
Centocor, The Netherlands, TNFi) as described [15]. After
anaesthesia using a ketamine hydrochloride/xylazine mix-
ture (80 and 12 mg/kg body weight, i.p.) the left leg was
fractured with three point bending. It was stabilized with
an intramedullary nail (hollow needle 23G) [16] (see also
Figure 1). Carprofen (4 mg/kg intra muscular) was given
as an analgesic and further on at 24 hour intervals when
required. Mice were euthanized by cervical dislocation 14
or 28 days after surgery. All experiments were performed
according to the protocol approved by the Animal Care
and Use Committee of the University Hospital Erlangen,
Germany.
Biomechanical analyses
For biomechanical analyses, mice (n = 10, each wild type,
hTNFtg or hTNFtg treated with Infliximab) were eutha-
nized 28 days after surgery. Both femurs were dissected
and prepared for biomechanical testing as described
previously [17,18]. Briefly, the proximal and distal ends
of each femur were embedded into two molds with bone
cement (Palacos R, Heraeus Kulzer GmbH, Germany).
Each mold was then connected to a pivoted axis. A
linear constant feed rate, generated by a material test-
ing machine (LR5Kplus, Lloyd Instruments, Meerbusch,
Germany), was loaded by a lever attached to one of the
pivoted axes. The bone was preloaded at an axial force
of 5 N and a constant linear propulsion (v = 1 mm/min)
was applied by the testing machine. The translation of
the material testing machine was transformed to an
uniform torsional movement. The free axis was connected
to a strain-gauge (Fmax = 250 N, XLC, Lloyd Instruments,
Meerbusch, Germany) that detected the torsional force.
The data were recorded using Catman32 software (HBM,
Darmstadt, Germany) and analyzed by Microsoft Excel
(Redmont, USA). The angle of failure and the maximum
load were determined as material characteristics and
the torsional stiffness (N/°) was calculated as a bio-
mechanical parameter. Each parameter was compared
with the values of the non-fractured contralateral femur
(ratio of fractured/non-fractured femur (100%)). Data
shown are medians with a range of up to 8 measure-
ments for each group.
Histomorphometry
For histomorphological analyses fractured femurs (n = 10,
each group) were embedded undecalcified in methyl-
methacrylate (Technovit® 9100, Heraeus, Germany).
Sagittal serial sections (5 μm) were stained with alcian
blue. Image Pro Plus software (ImagePro®Plus 7.0, Media
Cybernetics Inc., Bethesda, USA) was used to determine
and calculate the following histological parameters within
the area of interest (see also Figure 2A): whole callus area
(black line, cartilage area (dotted line)/total callus area
and area of soft tissue (dashed line)/total callus area.
The histological analysis was performed randomized
and blinded with regard to genotype and treatment.
Complicated fractures were excluded from the analysis.
The data shown are means with SD of up to10 mea-
surements of each group.
Statistic
Statistical analysis (Mann–Whitney-U-test: conducted be-
tween each group, non-parametric, two tailed, Confidence
Interval: 95%) was carried out using GraphPad Prism 5.02
(GraphPad Software, San Diego, USA). p-values >0.05
were regarded as significant, p-values between 0.05 and
0.1 indicate tendency.
Results
Clinical assessment
As described previously, the hTNFtg mice are smaller in
size and weight compared to their wild type littermates
Figure 1 Radiographs of a fractured femur after surgery OP (A)
and after 28 days of healing (B). Mouse femur fractured and stabilized
by an intramedullary nail (Schmidmaier et al., [18], modified).
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[14,19]. A treatment of these mice with a human anti-TNF
antibody prevents the development of an inflammatory
polyarthritis [14]. In our study, we used hTNFtg mice at the
age of 12 weeks for surgery and monitored the follow-up of
the healing process for up to 4 weeks. However, the animals
were smaller compared to wild type mice. This influenced
the outcome of fracturing and therefore the progression of
fracture healing. As shown by radiographic and histological
pictures, some fractures occurred near the knee joint
or were dislocated or fragmentary, and were therefore
excluded from further analyses.
Biomechanical bone stability after fracture
Two different material characteristics were measured,
that are influenced by the tissue composition during
fracture healing. Firstly, the force that is needed to break
the bone, characterized by maximum torque, as well the
angle of failure that is used as a parameter of the flexibility
of the bone, were measured. Secondly, the torsional stiff-
ness was calculated from these values as a measure for
the biomechanical stability of the bone. After 28 days
of healing there was no significant difference in the
maximum torque between the wild type group and both
hTNFtg groups, although the standard deviation was high
in the hTNFtg group without treatment (Figure 3). The
fractured femur yield almost 100% of the maximum
torque measured for the unfractured femur in all groups
(wild type: 89%, hTNFtg: 99.5%, hTNFtg + TNFi: 69%).
Interestingly, the angle of failure in the wild type group
(128%) was comparable to the hTNFtg + TNFi group
(98%), but significantly increased in the hTNFtg group
(221%, wild type vs. hTNFtg: p = 0.0293; hTNFtg vs.
hTNFtg + TNFi: p = 0.014). The torsional stiffness, how-
ever, was not significantly altered in the hTNFtg group
(69.3%) compared to both wild type (91.3%) and the
TNFi treated hTNFtg group (96%) (wild type vs. hTNFtg:
p = 0.345; hTNFtg vs hTNFtg + TNFi: p = 0.617).
Histomorphological analysis of fracture callus composition
after 14 and 28 days of healing
Further investigation of the callus tissue composition
provided an indication for the altered biomechanical
properties of the three different groups. Sagittal sections
of femurs were stained for cartilage using alcian blue
staining and for determination of the whole callus area
(Figure 2A). The area of cartilage (stained in blue; dotted
line) and the area of soft tissue (dashed line) were com-
pared in the callus area. These parameters change the
Figure 2 Histological analysis of the fracture callus composition
14 and 28 days after surgery. Alcian blue staining was performed
using sagittal section of the fractured femur. Using digital image analysis,
the area of different tissues was determined within the whole callus as
indicated in A. Overview of the tissue composition of a sagittal section of
a fractured femur: Area of whole callus, black line; cartilage area, dotted
line; soft tissue, dashed line. B: Comparison of the callus composition
after 14 and 28 days with wild type, hTNFtg and hTNFtg + TNFi group
within the site of fracture (AOI) after Alcian blue staining (representative
pictures, scale bar 500 μm).
Figure 3 Biomechanical analysis of the fractured femur. Torsional testing was applied to the fractured and unfractured femur of each animal.
Maximum torque [Nmm] and angle of failure [°] were determined and used for calculation of torsional stiffness [Nmm/°]. The ratio of fractured
femur/non-fractured femur [%] was calculated. Wild type: n = 8, hTNFtg: n = 6, hTNFtg + TNFi: n = 7, * p < 0.05; dashed line: p < 0.1, tendency.
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most within the investigated time points at day 14 and
day 28 (Figure 2). The quantitative analysis of all fracture
calli showed a significantly bigger callus area in the
hTNFtg and hTNFtg + TNFi treated groups compared
to the wild type group after 14 days (37%, Figure 4A)
and 28 days (30%, Figure 4D). Further investigation of
the composition surrounding the fracture site revealed
an increased area of soft tissue in the hTNFtg group
(24.1% vs. 11.4% (wild type, p = 0.0307) and 18.7%
(hTNFtg + TNFi) compared to the wild type at day 14
(Figure 4B). Additionally, the hTNFtg + TNFi group dis-
played twice as much cartilage than both other groups
on day 14 (18.4% vs 9.9% in wild type (p = 0.0234) or
7.6% in hTNFtg (p = 0.0159) (Figure 4C). After 28 days
the content of soft tissue was higher within the wild
type group (5.8% vs. 2.5% in wild type and 2% in
hTNFtg + TNFi; p < 0.1). The amount of cartilage in
wild type and hTNFtg + TNFi group was lower (0.8%)
compared to 14 days, but much less in hTNFtg without
treatment (0.18%) (Figure 4B). Furthermore, the area of
mineralized bone (trabecular bone within the callus
area) was determined, but there were no differences
within the three groups (Data not shown).
Discussion
The hTNFtg mouse is considered to be a valuable model
of human RA [19,20]. In these animals, overexpression of
human TNF-α induces severe inflammatory polyarthritis.
This arthritis shares many hallmarks with the human
counterpart, such as polyarticular involvement of the
small joints, chronic and progressive course of disease,
and the destruction of cartilage and subchondral bone.
The disease is driven by the overexpression of proin-
flammatory cytokines. The overexpression of TNF-α
was described as being responsible for a dramatic loss
of trabecular bone and, to a lesser extent, cortical bone
[20]. The influence of a chronic inflammation on fracture
healing, however, has not been studied. Therefore, we
used hTNFtg animals, with high systemic levels of TNF-α
to investigate its influence on the composition of the frac-
ture callus and the progression of the healing process.
The importance of TNF-α signaling during fracture
healing is commonly accepted today. On the one hand,
it is known that TNF-α expression increases soon after
injury [11,21]. During this inflammatory phase different
cell types, including mesenchymal stem cells, located in
the surrounding tissue, are recruited to the fracture site
and initiate the formation of the primary callus. Different
studies were able to demonstrate that deficiency of TNF-α
signaling causes a delay in callus remodeling with regard
to chondrocyte maturation and apoptosis in the later
phases of fracture healing [11,12,22]. On the other hand,
high levels of TNF-α contribute to accelerated loss of
cartilage during fracture healing as seen in diabetic
mice [23]. In our study we have demonstrated that high
systemic levels of TNF-α influence the biomechanical
stability and composition of the bone in the course of
fracture healing, lead to increased callus formation with
less cartilage and more soft tissue within the fracture
gap. These alterations of the callus composition resulted
in lowered biomechanical stability with a higher flexibility
of bone within the callus after 28 days of healing.
Figure 4 Quantification of the callus composition after 14 and 28 days of fracture healing using digital image analysis. A/D: Whole callus
area was determined [mm2]. Area of soft tissue (B/E) as well as Cartilage area (C/F) were measured as depicted in Figure 3A and displayed as a ratio
to the whole callus area [%]. Wild type: n = 10; hTNFtg: n = 5; hTNFtg + TNFi: n = 7, * p < 0.05, dashed line p < 0.1, tendency.
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Histologically, we found that the callus of hTNFtg animals
was built of less cartilage and more soft tissue com-
pared to the wild type which leads to an altered stability
of the callus. Therefore, our results indicate a negative
influence of chronically elevated TNF-α level during
the fracture healing process.
TNF-α-inhibitors like Infliximab are used in treatment
of rheumatic patients to bind TNF-α with high affinity
to reduce inflammatory symptoms [6,24]. The high effi-
ciency of the blocking hTNF antibody was proven within
the hTNFtg animal model [14]. Treated animals do not
show any signs of rheumatoid like disease. The influence
of a TNF-α-inhibitor on fracture healing, however, has
been investigated in a wild type rat model under non-
inflammatory conditions. In this case the authors did not
find any impairment of metaphysal bone healing [25].
Under chronic inflammatory conditions, as it was shown
in this study, the blockade of TNF-α during fracture
healing (by Infliximab treatment) led to an increased
callus size, which was accompanied by an increase in
cartilage tissue compared to the not treated group. After
28 days of fracture healing, the fracture callus composition
resembled the wild type situation. Biomechanical testing
revealed no differences compared to wild type fracture
healing. Treatment with Infliximab even seemed to com-
pensate the derogating effects of elevated systemic TNF-α
levels on fracture healing which can be concluded from
the similarity of the biomechanical and histological results
of the TNFi treated group compared to wild type in our
model. It might be interesting to further distinguish
between the negative effects of pathologically elevated
levels of TNF-α and the positive effects of endogenous
TNF signaling during fracture healing. This could be
done by performing studies using the fracture model
and dose dependent treatment with hTNF blocking
antibody and to look for the onset of callus development
and callus composition in the course of healing. Our re-
sults provide indication that rheumatoid arthritis patients,
who sustained a fracture during the treatment with TNF-α
antagonist, should continue this therapy.
Conclusion
Elevated TNF-α level have a negative impact on the
physiological development of the callus and thereby
impair fracture healing in this murine model of chronic
inflammation. We have found that the treatment of this
chronic inflammation during fracture healing is benefi-
cial and restores the biomechanical and morphological
condition as found in the wild type. Further studies on
fracture healing under chronic inflammatory conditions
in animal models and rheumatoid arthritis patients will
be necessary to further elucidate the mechanisms of
this positive effect of anti-TNFα-treatment.
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